Pluri (PLUR) AI Stock Analysis

• Market Cap: $28.87M
• Dividend Yield: N/A
• Average Volume (3M): 8.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 121.74%
• EPS Growth: 24.75%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 8,155,948
• 10 Day Avg. Volume: 13,380
• 30 Day Avg. Volume: 8,388
• PEG Ratio: 1.25
• Price to Book (P/B): -45.85
• Price to Sales (P/S): 234.79
• P/FCF Ratio: -15.82
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: 32.50
• Enterprise Value/Gross Profit: 75.75
• Enterprise Value/Ebitda: -1.95
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $3.50 ▼(-7.16% Downside)

Pluri's overall stock score is primarily impacted by its weak financial performance and challenging valuation. The bearish technical indicators further contribute to a low score, reflecting significant risks and uncertainties.

Positive Factors

Revenue Growth

Pluri's revenue growth of 29.21% indicates strong demand for its innovative therapies, suggesting potential for future market expansion.

Business Model

Pluri's diversified revenue streams from licensing, partnerships, and grants provide a robust foundation for long-term growth and resilience.

Industry Position

Pluri's focus on regenerative medicine and immunotherapy positions it well in a growing industry with high demand for innovative treatments.

Negative Factors

Financial Stability

Negative equity and high debt-to-equity ratio highlight financial instability, posing risks to long-term solvency and operational flexibility.

Cash Flow Challenges

Negative operating cash flow indicates ongoing operational challenges, limiting the company's ability to fund growth and innovation internally.

Profitability Issues

Persistent profitability issues, despite revenue growth, suggest high operational costs, affecting long-term financial sustainability.

Pluri Business Overview & Revenue Model

Company Description

Pluri (PLUR) is a biotechnology company focused on developing innovative therapies based on its proprietary technology platform for cell reprogramming and stem cell biology. Operating primarily in the healthcare and life sciences sectors, Pluri specializes in creating novel treatments for various diseases, particularly in regenerative medicine and immunotherapy. The company aims to harness the potential of pluripotent stem cells to address unmet medical needs and improve patient outcomes through advanced cellular therapies.

How the Company Makes Money

Pluri generates revenue through multiple streams, primarily by commercializing its proprietary technologies and cell therapy products. The company licenses its technology to pharmaceutical and biotechnology firms, which pay upfront fees and ongoing royalties based on sales of products developed using Pluri's platform. Additionally, Pluri engages in strategic partnerships and collaborations with research institutions and healthcare organizations, which often include funding arrangements for joint research projects. The company may also generate revenue from grants and funding from government and non-profit organizations aimed at supporting innovative medical research. Overall, Pluri's revenue model is driven by the successful development and commercialization of cutting-edge therapies, along with strategic collaborations that enhance its market reach.

Pluri Financial Statement Overview

Summary

Pluri faces significant financial challenges with persistent losses, negative equity, and weak cash flow. Despite revenue growth, the company's financial health remains precarious, requiring strategic changes to achieve stability and profitability.

Income Statement

Pluri's income statement reveals significant challenges with profitability. Despite a notable revenue growth rate of 29.21% in the latest year, the company struggles with negative net profit margins and EBIT margins, indicating ongoing losses. The gross profit margin has improved but remains insufficient to offset high operating expenses.

Balance Sheet

The balance sheet shows a concerning financial structure with negative stockholders' equity and a high debt-to-equity ratio in recent years. Although the debt-to-equity ratio improved in the latest year, the negative equity and low return on equity highlight financial instability and potential solvency risks.

Cash Flow

Pluri's cash flow statement indicates some improvement in free cash flow growth, but operating cash flow remains negative. The free cash flow to net income ratio suggests that cash flow is slightly better than net income figures, yet the overall cash flow position is weak, reflecting ongoing operational challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.33M	1.34M	326.00K	287.00K	234.00K	0.00
Gross Profit	569.00K	654.00K	322.00K	278.00K	-819.00K	-1.37M
EBITDA	-22.09M	-22.07M	-20.23M	-27.68M	-39.43M	-48.42M
Net Income	-22.83M	-22.58M	-20.89M	-28.32M	-41.24M	-49.87M
Balance Sheet
Total Assets	33.67M	38.68M	39.53M	50.80M	68.06M	93.54M
Cash, Cash Equivalents and Short-Term Investments	15.06M	20.61M	30.24M	40.17M	55.02M	64.95M
Total Debt	34.24M	34.05M	29.61M	29.91M	28.80M	24.58M
Total Liabilities	39.32M	39.55M	34.11M	35.50M	35.88M	36.39M
Stockholders Equity	-11.36M	-6.84M	96.00K	13.36M	30.04M	57.15M
Cash Flow
Free Cash Flow	-21.10M	-19.83M	-18.34M	-23.12M	-36.78M	-31.28M
Operating Cash Flow	-19.57M	-18.21M	-18.02M	-22.86M	-36.50M	-30.91M
Investing Cash Flow	11.29M	8.03M	10.58M	9.70M	11.78M	-7.26M
Financing Cash Flow	9.53M	9.53M	8.84M	8.02M	7.50M	61.40M

Pluri Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Neutral. The current price of 3.77 is above the 20-day moving average (MA) of 3.75, below the 50-day MA of 4.09, and below the 200-day MA of 4.60, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 47.42 is Neutral, neither overbought nor oversold. The STOCH value of 33.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PLUR.

Pluri Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MURA	43 Neutral	$36.04M	-0.24	-103.87%	―	―	24.16%
IGC	41 Neutral	$35.78M	-4.85	-83.34%	―	-6.51%	58.31%
PYPD	41 Neutral	$62.80M	―	-390.53%	―	―	61.23%
PLUR	41 Neutral	$28.87M	-1.01	―	―	121.74%	24.75%
ITRM	35 Underperform	$29.40M	-0.71	―	―	―	62.61%
ANTX	34 Underperform	$31.15M	-0.91	-45.91%	―	―	44.59%

Pluri Corporate Events

Pluri Approves Equity Awards for CEO Yaky Yanay

On October 15, 2025, Pluri Inc.’s board of directors approved a grant of equity awards to CEO Yaky Yanay for achieving certain performance objectives in fiscal year 2025. The awards include 39,050 fully vested restricted stock units and stock options for 39,050 shares, exercisable for three years at $5.00 per share. Additionally, contingent future grants of 9,266 RSUs and stock options were approved, pending the achievement of specific objectives by December 31, 2025.

The most recent analyst rating on (PLUR) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.

Pluri Resolves Nasdaq Compliance Issue with New Director

Pluri Inc. faced a compliance issue with Nasdaq’s Audit Committee independence requirements after a director was not elected at the annual shareholders meeting on June 30, 2025. The company resolved this by electing Mr. Eitan Ajchenbaum as an independent director and Audit Committee Chairman, leading Nasdaq to confirm compliance and close the matter.

The most recent analyst rating on (PLUR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.

Pluri Appoints Eitan Ajchenbaum to Board of Directors

On September 10, 2025, Pluri Inc. appointed Mr. Eitan Ajchenbaum to its board of directors, filling a vacancy left by Doron Birger after the annual shareholders meeting on June 30, 2025. Mr. Ajchenbaum, with extensive experience in finance and insurance, will serve as a non-executive director, chair the Audit Committee, and be the sole member of the Investment Committee, enhancing the company’s governance and strategic oversight.

The most recent analyst rating on (PLUR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.